Barnes & Thornburg Advises BlossomHill Therapeutics in $100 Million Series B Financing Round

Barnes & Thornburg’s corporate and intellectual property attorneys advised BlossomHill Therapeutics, Inc., a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, on its $100 million Series B financing round.

The financing, which brings the total capital raised by the company to $173 million, will be used to advance the company’s pipeline of in-house discovery and development programs for multiple high-needs cancers and autoimmune diseases.

The company is based in San Diego.

With more than 800 attorneys and other legal professionals, Barnes & Thornburg is one of the largest law firms in the country. The firm serves clients worldwide from offices in Atlanta, Boston, California, Chicago, Delaware, Indiana, Michigan, Minneapolis, New Jersey, New York, Ohio, Philadelphia, Raleigh, South Florida, Salt Lake City, Texas and Washington, D.C. For more information, visit us online at www.btlaw.com.